P/E ratio for Fresenius Medical Care (FMS)
P/E ratio as of July 2025 (TTM): 22.3
According to Fresenius Medical Care's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 22.2515. At the end of 2022 the company had a P/E ratio of 13.7.
P/E ratio history for Fresenius Medical Care from 2001 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 13.7 | -18.96% |
| 2021 | 16.9 | -7.29% |
| 2020 | 18.2 | 9.22% |
| 2019 | 16.7 | 94.83% |
| 2018 | 8.56 | -60.87% |
| 2017 | 21.9 | 7.02% |
| 2016 | 20.4 | -17.89% |
| 2015 | 24.9 | 15.58% |
| 2014 | 21.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Quest Diagnostics
DGX | 21.0 | -5.83% | 🇺🇸 USA |
 LabCorp LH | 30.0 | 34.97% | 🇺🇸 USA |
 DaVita DVA | 14.0 | -36.90% | 🇺🇸 USA |
 IDEXX Laboratories IDXX | 51.9 | 133.35% | 🇺🇸 USA |
 Baxter BAX | -951 | -4,372.37% | 🇺🇸 USA |
 Rockwell Medical
RMTI | -25.8 | -215.72% | 🇺🇸 USA |
 Amgen AMGN | 27.3 | 22.54% | 🇺🇸 USA |
 Teleflex TFX | 36.0 | 61.79% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.